



An Anthem Company

NEW YORK Provider Communications

Clinical criteria updates for specialty pharmacy

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Empire BlueCross BlueShield's ("Empire") pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by Empire's medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health (AIM), a separate company.

The following Clinical Criteria documents were endorsed at a Clinical Criteria meeting. To access the clinical criteria information please click [here](#).

Revised Clinical Criteria effective August 1, 2021

The following clinical criteria were reviewed with no significant change to the medical necessity indications or criteria.

- ING-CC-0037 Kanuma (sebelipase alfa)
- ING-CC-0043 Monoclonal Antibodies to Interleukin-5
- ING-CC-0057 Krystexxa (pegloticase)
- ING-CC-0066 Monoclonal Antibodies to Interleukin-6
- ING-CC-0068 Growth Hormone
- ING-CC-0069 Egrifta (tesamorelin)
- ING-CC-0111 Nplate (romiplostim)
- ING-CC-0137 Cablivi (caplacizumab-yhdp)
- ING-CC-0153 Adakveo (crizanlizumab)
- ING-CC-0162 Tepezza (teprotumumab-trbw)

1249-0821-PN-NY

URL: <https://providernews.empireblue.com/article/clinical-criteria-updates-for-specialty-pharmacy-60>

Featured In:

August 2021 Newsletter

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.
